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Larynx tumor is a rare neoplasia that represent only the 2%
 
of all human tumor. In particular, the 
90% of tumor that occur
 
in this organ correspond to the laryngeal squamous cell carcinoma
 
(LSCC). 
From the biomolecular point of view, it was shown that
 
the TP53 gene mutations are the most 
common events observed
 
in the early phases of LSCC carcinogenesis. However, them prognostic
 
significance remains controversial. Besides, the prognostic
 
significance of DNA ploidy has been 
well established for other
 
solid tumors, but its role in LSCC is still controversial. The
 
aim of this 
study was, therefore, to prospectively evaluate
 
the prognostic significance of TP53 mutations, 
DNA-ploidy and
 
S-phase fraction (SPF) in LSCC patients. Prospective analysis
 
of 81 patients who 
underwent resective surgery for primary operable
 
locally advanced LSCC patients (stages III and 
IV) was performed.
 
Tumor DNA was screened for TP53 mutations by PCR/SSCP and sequencing;
 
DNA flow cytometry was performed on mechanically disaggregated
 
sample of frozen tumor tissue. 
The median follow-up time in
 
our study group was 71 months (range 11-137 months). Fourthy-four
 
percent of patients (36/81) have, at least, a mutation in the
 
TP53 gene. Of them, 22% (8/36) have 
double mutations and 6%
 
(2/36) have triple mutations. In total, 47 TP53 mutations were
 
observed. 
The majority (42%) of these occur in exon 5 (20/47),
 
while the mutations in exons 6, 7 and 8 are 
represented in 14,
 
7 and 6 patients respectively (30%, 15% and 13%). The flow cytometry
 
analysis 
showed that sixty-three percent of the cases (51/81)
 
were DNA aneuploidy and 14% of these (7/51) 
were multiclonal.
 
LSCC patients were divided into two groups using median SPF
 
level as cut-off 
point: low SPF 15.1 % and high SPF >15.1
 
%, Even though it seems that TP53 mutations promotes 
the LSCC
 
carcinogenesis in young people (p< 0.05), there was not any
 
association between this 
variable and the clinicopathological
 
or the other biomolecular variables. At univariate analysis,
 
the 
Kaplan and Meier text show that DNA aneuploidy, high SPF,
 
any TP53 mutations and, in 
particular, the mutations that occur
 
in exons 5 and 8 proved to be significantly related to quicker
 
disease relapse and short OS. At multivariate analysis, the
 
Cox proportional hazards model show 
that the major significant
 
predictors for both disease relapse and death were high SPF
 
and any TP53 
mutations. In conclusion, any TP53 mutations, more
 
than specific mutations in exon 5 and 8, are 
important biological
 
indicators to predict the outcome of patients indicating these
 
mutations have 
biological relevance in terms of LSCC disease
 
course. Our study has also identify high SPF as 
independent
 
prognostic factors in locally advanced LSCC patients.
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